Disc Medicine (IRON) Non-Current Debt (2020 - 2021)
Disc Medicine (IRON) reported Non-Current Debt of $404000.0 for Q4 2021, down 91.84% year-over-year from $5.0 million in Q4 2020, and down 75.47% on a QoQ basis from $1.6 million in Q3 2021.
Disc Medicine (IRON) has 2 years of Non-Current Debt data on file, last reported at $404000.0 in Q4 2021.
- Quarterly Non-Current Debt fell 91.84% year-over-year to $404000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $404000.0 (down 91.84% YoY) and the FY2021 annual result came in at $404000.0, down 91.84% from the prior year.
- Non-Current Debt declined to $404000.0 in Q4 2021 per IRON's latest filing, from $1.6 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $5.0 million in Q4 2020 and bottomed at $404000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 404,000.00 |
| Dec 31, 2021 | 404,000.00 |
| Sep 30, 2021 | 1.65 Mn |
| Sep 30, 2021 | 1.65 Mn |
| Jun 30, 2021 | 2.89 Mn |
| Jun 30, 2021 | 2.89 Mn |
| Mar 31, 2021 | 4.13 Mn |
| Mar 31, 2021 | 4.13 Mn |
| Dec 31, 2020 | 4.95 Mn |
| Dec 31, 2020 | 4.95 Mn |